Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
Wong Tina T, Aung Tin, Ho Ching Lin
AI Summary
Switching glaucoma patients from latanoprost to low-preservative tafluprost improved ocular surface disease and symptoms, offering a better-tolerated treatment option with comparable IOP control.
Abstract
Importance
Glaucoma treatment has often been associated with adverse side-effects from preservatives that are included in the used eye drops.
Background
To evaluate changes in the ocular surface and the presence of prostaglandin-induced corneal disorders after being switched from latanoprost 0.005% to low preservative tafluprost 0.0015% ophthalmic solution.
Design
Single centre, prospective study.
Participants
Patients with primary open-angle glaucoma or ocular hypertension that had received treatment with once daily latanoprost 0.005% ophthalmic solution for control of intraocular pressure (IOP) for 3 months, with a score of above 1 on the National Eye Institute (NEI) ocular surface staining scale.
Methods
Following the ≥3 month latanoprost treatment period, patients were switched to once daily low preservative tafluprost 0.0015% ophthalmic solution. Patients were followed for a minimum of 3 months.
Main outcome measures
Ocular surface changes were assessed by fluorescein staining score (NEI scale). Additional evaluations included tear break-up time, hyperaemia score, subjective symptoms, changes in intraocular pressure and presence of adverse reactions.
Results
Out of 59 patients enrolled, 51 were included in the final analysis. Fluorescein staining scores at baseline, prior to treatment switch, were 6.9 ± 3.1 and 3.3 ± 2.7 at the end of the study period (change in scores was -3.6 ± 2.2 [P < 0.001]). At last follow-up, significant improvements were observed in tear break-up time, hyperaemia score and subjective symptoms (all P < 0.05).
Conclusions and relevance: The clinical signs of ocular surface disease and subjective symptoms of dry eyes improved following the switch to low preservative tafluprost and demonstrated comparable IOP lowering effectiveness.
MeSH Terms
Shields Classification
Key Concepts4
In patients with primary open-angle glaucoma or ocular hypertension, fluorescein staining scores at baseline, prior to treatment switch from latanoprost 0.005% to low preservative tafluprost 0.0015% ophthalmic solution, were 6.9 ± 3.1 and 3.3 ± 2.7 at the end of the study period (change in scores was -3.6 ± 2.2 [P < 0.001]).
In patients with primary open-angle glaucoma or ocular hypertension, significant improvements were observed in tear break-up time, hyperaemia score, and subjective symptoms (all P < 0.05) following the switch from latanoprost 0.005% to low preservative tafluprost 0.0015% ophthalmic solution.
The clinical signs of ocular surface disease and subjective symptoms of dry eyes improved following the switch to low preservative tafluprost and demonstrated comparable IOP lowering effectiveness in patients with primary open-angle glaucoma or ocular hypertension.
Patients with primary open-angle glaucoma or ocular hypertension that had received treatment with once daily latanoprost 0.005% ophthalmic solution for control of intraocular pressure (IOP) for 3 months, with a score of above 1 on the National Eye Institute (NEI) ocular surface staining scale, were switched to once daily low preservative tafluprost 0.0015% ophthalmic solution.
Related Articles5
How latanoprost changed glaucoma management.
ReviewShort-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Clinical TrialSpanish multicenter tafluprost tolerability study.
Observational StudyEffects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
Randomized Controlled TrialA phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension.
Randomized Controlled TrialIs this article assigned to the wrong chapter(s)? Let us know.